Pharmacogenetics of treatment with leukotriene modifiers

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 5, 2002, Pages 395-401

  Wechsler, Michael E ^a   Israel, Elliot ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

5 LO; Leukotriene modifiers; LTC4 synthase; Pharmacogenetics

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MONTELUKAST; ZAFIRLUKAST;

ASTHMA; DISEASE ASSOCIATION; GENE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0036772346     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200210000-00005     Document Type: Review

References (50)

1. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405:857-865.
2. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharrnacogenetics of asthma. Am J Respir Crit Care Med 2002; 165:861-866. An excellent up-to-date review of the pharmacogenetics of different asthma therapies.
3. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054-1070.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
5. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335:841-847.
6. 1 and methacholine responsiveness, but there is increased adrenal suppression.
7. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta (2)-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188.
8. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80. A key beta-agonist pharmacogenetics study demonstrating tachyphylaxis with regular beta-agonist use depending on beta receptor genotype.
9. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta-agonist use: Influence of beta2 adrenoceptor polymorphism. Thorax 2000; 55:762-767. Another important beta agonist receptor gene pharmacogenetics study demonstrating an association between beta receptor genotype and asthma exacerbations.
10. Hall IP. Pharmacogenetics of asthma. Eur Respir J 2000; 15:449-451.
11. D'Amato M, Vitiani LR, Petrelli G, et al. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study. Am J Respir Crit Care Med 1998; 158:1968-1973.
12. Barnes KC. Atopy and asthma genes - Where do we stand? Allergy 2000; 55:803-817.
13. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483-10488. This highlights the importance of looking at haplotypes when assessing genotypephenotype associations.
14. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
15. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146:104-108.
16. Lam S, Chan H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81:711-717.
17. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142:112-119.
18. Drazen JM. Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 1986; 89:414-419.
19. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized controlled trial. Ann Intern Med 1999; 130:487-495.
20. Woods JW, Evans JF, Ethier D, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178:1935-1946.
21. Schleimer RP, MacGlashan Jr DW, Peters SP, et al. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986; 133:614-617.
22. 4. Proc Natl Acad Sci USA 1983; 80:7626-7630.
23. 4 from alveolar macrophages. Nature 1982; 297:329-331.
24. Schonfeld W, Schluter B, Hilger R, Konig W. Leukotriene generation and metabolism in isolated human lung macrophages. Immunology 1988; 65:529-536.
25. Holtzman MJ. Arachidonic acid metabolism in airway epithelial cells. Annu Rev Physiol 1992; 54:303-329.
26. Eling TE, Danilowicz RM, Henke DC, et al. Arachidonic acid metabolism by canine tracheal epithelial cells. Product formation and relationship to chloride secretion. J Biol Chem 1986; 261:12841-12849.
27. 4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986; 261:16466-16472.
28. Jackson RM, Chandler DB, Fulmer JD. Production of arachidonic acid metabolites by endothelial cells in hyperoxia. J Appl Physiol 1986; 61:584-591.
29. 4 from porcine pulmonary artery. Prostaglandins 1984; 28:905-914.
30. Deykin A, Israel E. Newer therapeutic agents for asthma. Dis Month 1999; 45:117-144.
31. 4. J Immunol 1991; 146:2671-2677.
32. 4 receptor in human myeloid cells. Eur J Pharmacol 1993; 244:161-173.
33. 4 in inflammation. Crit Rev Immunol 1990; 10:1-12.
34. 2. J Lipid Mediat 1993; 6:175-181.
35. 4 12-hydroxydehydrogenase. J Biol Chem 1996; 271:2844-2850.
36. 4. Mol Pharmacol 1987; 32:223-229.
37. 4 receptors. Mol Pharmacol 1987; 31:35-41.
38. 4 receptor. Trends Pharmacol Sci 1989; 10:103-107.
39. Crooke ST, Sarau H, Saussy D, et al. Signal transduction processes for the LTD4 receptor. Adv Prost Thromb Leukotr Res 1990; 20:127-137.
40. Drazen JM, Yandava C, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:170-172.
41. Anderson W, Kalberg C, Edwards L, et al. Effects of polymorphisms in the promoter region of 5-lipoxygenase and LTC4 synthase on the clinical response to zafirlukast and fluticasone. Eur Resp J 2000; 16 (Suppl B):183S. One of few pharmacogenetic studies of LTMs, it corroborates Drazen 5-LO promoter data.
42. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (Suppl 2):S28-S31. Although it is a study with a small number of subjects, the trend in differential response based on LTC4 synthase polymorphisms suggests that this locus too may have role in determining response to asthma therapy.
43. Hoshiko S, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 1990; 87:9073-9077.
44. In KH, Asano K, Beier J, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter which modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130-1137.
45. Silverman ES, Du J, DeSanctis GT, et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 1998; 19:316-323.
46. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. ARRD 1993; 148:1447-1451.
47. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290-296.
48. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834-846.
49. 4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106:72-76.
50. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107:3-8.